Anavex Life Sciences Corp
$ 4.57
24.52%
03 Dec - close price
- Market Cap 408,321,000 USD
- Current Price $ 4.57
- High / Low $ 4.84 / 3.80
- Stock P/E N/A
- Book Value 1.09
- EPS -0.54
- Next Earning Report 2026-02-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.43 %
- 52 Week High 14.44
- 52 Week Low 2.86
About
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to pioneering effective therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. Leveraging its proprietary drug discovery platform, Anavex is advancing a robust pipeline of innovative drug candidates that target the root causes of these disorders. The company's commitment to precision medicine is supported by extensive preclinical and clinical data, as well as strategic collaborations that enhance its research capabilities. With a seasoned team of professionals, Anavex is poised to make meaningful advancements in the neuroscience sector, aiming to significantly improve patient outcomes in this critical area of healthcare.
Analyst Target Price
$22.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-25 | 2025-08-12 | 2025-05-07 | 2025-02-05 | 2024-11-25 | 2024-08-06 | 2024-05-09 | 2024-02-07 | 2023-11-27 | 2023-08-08 | 2023-05-09 | 2023-02-07 |
| Reported EPS | -0.11 | -0.16 | -0.1316 | -0.14 | -0.14 | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 | -0.17 | -0.17 |
| Estimated EPS | -0.1426 | -0.1457 | -0.15 | -0.17 | -0.17 | -0.16 | -0.11 | -0.14 | -0.15 | -0.17 | -0.19 | -0.19 |
| Surprise | 0.0326 | -0.0143 | 0.0184 | 0.03 | 0.03 | 0.02 | -0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Surprise Percentage | 22.8612% | -9.8147% | 12.2667% | 17.6471% | 17.6471% | 12.5% | -18.1818% | 21.4286% | 20% | 17.6471% | 10.5263% | 10.5263% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1263 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVXL
2025-10-14 09:50:42
This article provides an in-depth analysis of the Blarcamesine Market, forecasting its growth and outlining key business strategies. The report highlights dominant players like Anavex Life Sciences and details market segmentation by product type, application, end-user, and region. It also discusses the research methodology and key reasons for purchasing the comprehensive market report from Coherent Market Insights.
2025-10-12 07:11:44
Wealth Enhancement Advisory Services LLC has reported a $160,000 stake in Anavex Life Sciences Corp. (AVXL). Several other institutional investors like PVG Asset Management Corp, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Rafferty Asset Management LLC, Wellington Management Group LLP, and E Fund Management Co. Ltd. have also adjusted their holdings in the biotechnology company. Anavex Life Sciences develops therapeutics for central nervous system diseases, including Alzheimer's and Parkinson's.
2025-10-10 11:40:00
Anavex Life Sciences Corp. announced that Prof. Dr. Timo Grimmer presented on "Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine" at the 35th Alzheimer Europe Conference. The presentation highlighted their lead drug candidate, ANAVEX®2-73 (blarcamesine), for Alzheimer's disease. Anavex is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders.
2025-09-30 08:30:00
Anavex Life Sciences announced the publication of results from its Phase IIb/III Alzheimer’s Disease trial for oral blarcamesine, highlighting significant clinical and quality of life improvements for early Alzheimer’s patients using a novel precision medicine approach. The publication confirms blarcamesine's superior clinical efficacy, strong safety profile, and potential to benefit up to 70% of early Alzheimer's patients by targeting genetically relevant populations. This oral, once-daily small molecule is believed to enhance the brain’s autophagy mechanism, potentially reducing the medical and economic burden of the disease.
2025-09-24 20:38:00
H.C. Wainwright has reiterated its 'Buy' rating on Anavex Life Sciences Corp. (AVXL) with a $42 price target, following new Phase 2b/3 Alzheimer’s data. The company's shares are trading below this target, suggesting significant upside potential. Anavex recently announced positive results for its oral therapy blarcamesine in reducing cognitive decline in early Alzheimer’s patients.
2025-09-09 15:31:00
Anavex Life Sciences presented at the H.C. Wainwright 27th Annual Global Investment Conference, detailing advancements in their Alzheimer's treatment, Blarcamesine, which is under EMA regulatory review. The company highlighted its strong financial position with over three years of cash runway and no debt, a robust pipeline for various neurological disorders, and promising clinical data showing superior safety and efficacy compared to currently approved Alzheimer's drugs. Anavex is exploring both partnership and independent commercialization strategies for its treatments.
